AC
BBIO icon

Aristeia Capital’s BridgeBio Pharma BBIO Stock Holding History

Aristeia Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-661,000
Closed -$18.1M – 442
2024
Q4 		$18.1M Buy
+661,000
New +$17.1M 0.6% 26

Other funds holding BBIO

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Aristeia Capital's BBIO Position: Q2 2025 in Review

Aristeia Capital sold out of BridgeBio Pharma (BBIO) in Q2 2025, closing a stake of 23,582 shares — an estimated $815K sold.

Aristeia Capital first reported a position in BBIO in Q1 2022 and held it in 8 quarters. The position peaked at $11.3M in Q4 2024. 359 funds tracked by Wall St. Rank hold BBIO as of Q2 2025.

  • Aristeia Capital reported no remaining BridgeBio Pharma position as of Q2 2025 after selling out during the quarter.
  • Aristeia Capital sold 23,582 BridgeBio Pharma shares in Q2 2025, an estimated $815K.
  • Aristeia Capital first reported a position in BridgeBio Pharma in Q1 2022 and held it in 8 quarters.
  • Aristeia Capital's BridgeBio Pharma position peaked at $11.3M in Q4 2024.
  • 359 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2025.

Based on Aristeia Capital's 13F filing for Q2 2025, filed 14 Aug 2025.